Biotech and Pharmaceuticals Pharmaceuticals

  • LONDON, Dec 10- Britain's economy lost speed in the three months to October, reflecting lower car sales and factory stoppages due to weaker demand that business groups blamed on uncertainty about Brexit. The Office for National Statistics also highlighted a jump in Britain's trade deficit for the three months to September compared with previous figures,...

  • *William Anderson to replace O'Day as Roche Pharmaceuticals CEO. *Gilead names Gregg Alton as interim CEO. Dec 10- Drugmaker Gilead Sciences Inc on Monday named Roche Holding AG's Daniel O'Day as its new chief executive, tapping an industry veteran to fill a management vacuum.

  • Dec 10- Drugmaker Gilead Sciences Inc named Roche Holding AG executive Daniel O'Day as its new chief executive officer, the companies said on Monday. Gilead said its board had appointed Gregg Alton as interim Chief Executive for the period of January 1, 2019 until O'Day's start date of March 1, 2019. The news of O'Day's hiring comes about four months after Gilead...

  • Dec 9- Drugmaker Gilead Sciences Inc will name Roche Holding AG executive Daniel O'Day as its new chief executive officer, according to a source familiar with the matter. It is not clear when O'Day, currently the CEO of Roche Pharmaceuticals, will start at Gilead. The news of O'Day's hiring comes about four months after Gilead said in July that it's Chief Executive...

  • FRANKFURT, Dec 7- Shares in Fresenius dropped as much as 13 percent on Friday after the healthcare group warned of stagnant profits next year and abandoned its 2020 targets, saying it needed to invest more money in its hospitals and other businesses. "There are market opportunities that present themselves that we need to capture for the long-term wellbeing of...

  • SHANGHAI, Dec 7- China's main equity market indexes ended flat on Friday in thin trade as investors remained cautious after the arrest of a senior Huawei executive sparked a global sell-off on fears it could derail hopes for a lasting U.S.- China trade detente. **Shares in China's drugmakers slumped, as investor worries deepened over the steep price cuts...

  • *FDA approved combination therapy for a type of lung cancer. Dec 6- Swiss drugmaker Roche Holding AG said on Thursday that its Tecentriq immunotherapy in combination with Avastin and chemotherapy won U.S. Food and Drug Administration approval as a first-line treatment for a type of lung cancer. The long-awaited FDA decision is a shot in the arm to Roche's...

  • Dec 6- Swiss drugmaker Roche Holding AG said on Thursday that its Tecentriq immunotherapy in combination with chemotherapy was approved by the U.S. Food and Drug Administration as a first-line treatment for a form of lung cancer. The Tecentriq regimen showed significant survival benefit in the initial treatment of metastatic non-squamous non-small cell...

  • Mallinckrodt's shares fell 7.5 percent to $21.41 on Thursday morning. The generics business, which generated revenue of $839.5 million in fiscal 2017, largely makes opioid drugs and has come under pressure as more doctors in the United States shy away from prescribing the addictive medicines that had claimed nearly 50,000 lives last year.

  • BOSTON, Dec 6- A unit of Johnson& Johnson will pay $360 million to resolve an investigation into its financial support of a charity that helped Medicare patients cover out-of-pocket drug costs, the U.S. Justice Department said on Thursday. The government alleged Actelion from 2014 to 2015 used a charity as a conduit to improperly pay the co-pay obligations of...

  • BOSTON, Dec 6- A unit of Johnson& Johnson has agreed to pay the U.S. government $360 million to resolve an investigation into its financial support of charities that help Medicare patients cover out-of-pocket drug costs, the U.S. Justice Department said on Thursday. The investigation, led by the U.S. Attorney's Office for the District of Massachusetts, has led to...

  • Dec 6- Drugmaker Mallinckrodt Plc said on Thursday it planned to spin off its specialty generics business to shareholders by the second half of 2019..

  • LEIGHTON BUZZARD, England, Dec 5- In a vast warehouse complex 40 miles north of London, staff are wrestling with ways to cram in more goods after a surge in demand from companies building stockpiles ahead of Brexit. Efforts at Miniclipper Logistics to add new racks by narrowing the aisles are being duplicated across Britain as Brexit contingency plans spark a...

  • OSAKA, Dec 5- Takeda Pharmaceutical has won shareholder approval for its $59 billion takeover of London- listed Shire, creating a global powerhouse that has a stronger drugs pipeline but is also saddled with massive debt. The company's high debt levels were a top concern for Takeda shareholders who gathered at an extraordinary meeting in Osaka, western Japan,...

  • FRANKFURT, Dec 5- German drugmaker Bayer, which acquired seed company Monsanto this year, said it aimed to increase adjusted core earnings to 16 billion euros in 2022, up from an expected 12.2 billion euros this year. The recently announced efficiency and structural measures will further support us in these endeavors, "Chief Executive Werner Baumann said at the...

  • ZURICH, Dec 4- Novartis said on Tuesday it was taking its experimental medicine ligelizumab to late-stage trials after the drug showed signs of outperforming existing product Xolair in treating severe urticaria, also known as hives. Xolair is sold by both Novartis and Roche, but has lost patent protection in Europe and the United States, leaving it exposed to...

  • $75/ share is 110 pct premium, deal dilutive for 2 years. LONDON, Dec 3- GlaxoSmithKline has agreed to buy U.S. cancer specialist Tesaro for $5.1 billion, marking a major biotech investment by Chief Executive Emma Walmsley as she seeks to rebuild the group's pharmaceuticals business. Britain's biggest drugmaker is paying $75 a share for the business, an 110 percent...

  • Dec 3- Israel- based RedHill Biopharma Ltd said on Monday its combination antibiotic met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine. RedHill estimates 2.5 million patients are treated annually for H. pylori bacterial infections in the United States.

  • LONDON, Dec 3- GlaxoSmithKline said on Monday it had agreed to buy U.S. cancer drug specialist Tesaro for $5.1 billion, marking a major biotech investment by the British drugmaker as its seeks to rebuild its pharmaceuticals portfolio.

  • Dec 3- Netherlands- based biopharmaceutical company argenx SE said it signed a deal with Cilag GmbH International, an affiliate of Johnson& Johnson's Janssen Pharmaceutical Companies unit, to develop its Cusatuzumab drug in certain types of cancer. Janssen will pay argenx $300 million in upfront cash payment, while Johnson& Johnson Innovation will make an...